Werewolf posts Q2 2026 net income after Jazz deal, sets H2 update plans for WTX-124, WTX-330
Werewolf said it expects to report strategic-review and clinical trial updates in the second half of 2026 after closing its JZP898 sale to Jazz and repaying its K2 loan.
Werewolf Therapeutics said it expects to provide additional updates in the second half of the year on the strategic alternatives process being run with Piper Sandler & Co., as well as data updates on its clinical trials of WTX-124 and WTX-330.1
The update follows two transactions completed during the quarter. CEO Daniel J. Hicklin said Werewolf entered into an asset purchase agreement with Jazz Pharmaceuticals Ireland Limited for the JZP898 program, which had previously been licensed to Jazz, and repaid all amounts owed under its loan and security agreement with K2 HealthVentures LLC.1 He said together these transactions, which included a $21.0 million payment to Werewolf, enabled the company to explore multiple options for continued development of its INDUKINE and INDUCER platforms and programs.1
On the pipeline, Werewolf's PREDATOR platform is used to design conditionally activated INDUKINE and INDUCER molecules intended to remain inactive in peripheral tissue but activate selectively in the tumor microenvironment.1 The company said its most advanced clinical-stage candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 and Interleukin-12 INDUKINE molecules for the treatment of solid tumors.1 It also said it has leveraged positive data from its INDUKINE molecules to advance INDUCER candidates, with its first two, WTX-1011 and WTX-2022, aimed at the STEAP1 target for prostate cancer and the CDH6 target for ovarian and kidney cancer.1
On finances, the company reported cash and cash equivalents of $22.0 million as of June 30, 2026, compared to $46.5 million as of March 31, 2026.1 It said based on its current operating plan, it expects to be able to fund its operations into the second quarter of 2027.1
Regarding the strategic review, Werewolf said it does not have a defined timeline for the exploration and evaluation of strategic alternatives and cannot confirm the process will result in any strategic alternative being announced or consummated, nor can it commit to whether such activities will produce any agreements or transactions that enhance stockholder value.1 The company added it does not intend to disclose further developments during this process unless its board of directors approves a specific action or it otherwise determines further disclosure is appropriate.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.